Can we introduce evidence based prescribing of complementary drug therapies into primary care? A randomised controlled trial.
| ISRCTN | ISRCTN19338940 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN19338940 |
| Secondary identifying numbers | N/A |
- Submission date
- 01/11/2005
- Registration date
- 20/12/2005
- Last edited
- 19/07/2010
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Musculoskeletal Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Not provided at time of registration
Contact information
Prof Maria Paola Dey
Scientific
Scientific
Department of Public Health
Bury Primary Care Trust
21 Silver Street
Bury
BL9 0EN
United Kingdom
| MPDey@uclan.ac.uk |
Study information
| Study design | Cluster randomised controlled trial |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised controlled trial |
| Study setting(s) | GP practice |
| Study type | Treatment |
| Scientific title | |
| Study objectives | To determine the impact of dissemination to GPs of a recommendation about glucosamine sulphate for knee osteoarthritis, endorsed by Bury PCT Medicines Subgroup on: 1. The frequency with which glucosamine sulphate is prescribed in primary care 2. The appropriateness of prescribing 3. The frequency with which non-steroidal anti-inflammatory drug (NSAID)/COX2 inhibitors are prescribed 4. The frequency of serious NSAID associated gastrointestinal effects |
| Ethics approval(s) | Approved by the Oldham research ethics committee (ref: 03/OL/105) Last amendment 13/06/2004. |
| Health condition(s) or problem(s) studied | Osteoarthritis |
| Intervention | Dissemination of a recommendation for the prescribing of glucosamine for knee osteoarthritis endosed by the Bury PCT Medicines Management Subgroup and accompanied by a letter of support signed by the Director of Public Health, Bury PCT. |
| Intervention type | Drug |
| Pharmaceutical study type(s) | |
| Phase | Not Specified |
| Drug / device / biological / vaccine name(s) | Glucosamine sulphate |
| Primary outcome measure | Change in the mean number of prescriptions for glucosamine sulphate 500 mg per general practitioner over study period. |
| Secondary outcome measures | 1. Change in cost to the NHS of prescriptions for glucosamine per general practitioner over study period 2. Proportion of GP prescribing glucosamine sulphate 500 mg during study period 3. If sufficient change in prescribing observed, number of admissions for gastrointestinal bleeding 4. Change in mean number of prescriptions of NSAID and COX2 |
| Overall study start date | 26/06/2004 |
| Completion date | 01/07/2005 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Sex | Both |
| Target number of participants | 55 general practitioners |
| Key inclusion criteria | General practitioners in Bury PCT |
| Key exclusion criteria | General practitioners on the local medicines management subgroup and the other GPs in their practices |
| Date of first enrolment | 26/06/2004 |
| Date of final enrolment | 01/07/2005 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centre
Department of Public Health
Bury
BL9 0EN
United Kingdom
BL9 0EN
United Kingdom
Sponsor information
Bury Primary Care Trust (UK)
Hospital/treatment centre
Hospital/treatment centre
21 Silver Street
Bury
BL9 0EN
England
United Kingdom
| Website | http://www.burypct.nhs.uk |
|---|
Funders
Funder type
Government
Bury Primary Care Trust (UK)
No information available
Results and Publications
| Intention to publish date | |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Not provided at time of registration |
| Publication and dissemination plan | Not provided at time of registration |
| IPD sharing plan |
